ZEISS Announces MyoActive Lens With Dynamic Signal Theory for Myopia Control

ZEISS Vision Care announced MyoActive, a spectacle lens for children with myopia, on October 1 from its Aalen headquarters. The company claims it is its most effective myopia management lens to date, utilizing "Dynamic Signal Theory" and patented M.O.V.E. technology to prevent visual adaptation to the myopia control signal. In a randomized controlled trial conducted by the Shanghai Eye Disease Prevention and Treatment Center involving 56 children aged 7–13, ZEISS reported that MyoActive wearers showed 0.60D less myopia progression and 0.22mm less axial elongation compared to a single-vision control group over 12 months. Mean progression was -0.23D per year. The data are currently listed as "data on file" and have not been peer-reviewed. Australian availability, pricing, and regulatory status were not included in the announcement.